Granulocyte-Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia

doi:10.1056/NEJM199506223322503

Volume 332:1671-1677		June 22, 1995		Number 25

Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia

Richard M. Stone, M.D., Deborah T. Berg, R.N., Stephen L. George, Ph.D., Richard K. Dodge, M.S., Paolo Alberto Paciucci, M.D., Philip Schulman, M.D., Edward J. Lee, M.D., Joseph O. Moore, M.D., Bayard L. Powell, M.D., Charles A. Schiffer, M.D., for The Cancer and Leukemia Group B

Full Text

PDF

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

PubMed Citation

ABSTRACT

Background Elderly patients with primary acute myelogenous leukemia(AML) are less likely to enter remission than younger adults,in part because of a higher mortality rate related to severemyelosuppression. Granulocyte–macrophage colony-stimulatingfactor (GM-CSF) has been shown to shorten the duration of neutropeniaand decrease infectious complications when administered afterchemotherapy to patients with lymphomas and solid tumors.

Methods We randomly assigned 388 patients 60 years of age orolder who had newly diagnosed primary AML to receive placeboor GM-CSF (5 µg per kilogram of body weight per day intravenously)in a double-blind manner, beginning the day after the completionof three days of daunorubicin and seven days of cytarabine.If leukemic cells persisted in the marrow three weeks afterthe initiation of chemotherapy, further daunorubicin (two days)and cytarabine (five days) were administered. GM-CSF or placebowas given daily until the neutrophil count was at least 1000per cubic millimeter, there was evidence of the regrowth ofleukemia, or severe toxic effects attributable to the studyinfusion occurred. Patients who had a complete remission werethen randomly assigned to receive one of two intensificationregimens.

Results Of 388 patients (median age, 69 years), 193 were randomlyassigned to receive GM-CSF and 195 to receive placebo. The rateof complete remission was 51 percent (95 percent confidenceinterval, 44 to 59 percent) among those assigned to GM-CSF and54 percent (95 percent confidence interval, 47 to 61 percent)among those assigned to placebo (P = 0.61). The reasons forfailure (early death, death during marrow hypoplasia, and persistentleukemia), the incidence of severe or lethal infection, andthe incidence of the regrowth of leukemia (2 percent overall)were similar in the two groups. The median duration of neutropeniawas slightly shorter (P = 0.02) in the patients who receivedGM-CSF (15 days) than in those who received placebo (17 days),but the clinical importance of this result was minimal becausethe growth factor failed to lower the treatment-related mortalityrate or improve the rate of complete remission.

Conclusions GM-CSF, in the dose and schedule we used, does notstimulate the regrowth of leukemia, but it also does not decreasethe severe myelosuppressive consequences of initial chemotherapyor improve the response rate in patients 60 years of age orolder with primary AML. It should not be recommended for usein such patients.

Source Information

From the Division of Medical Oncology, Dana–Farber Cancer Institute, and the Department of Medicine, Harvard Medical School, Boston (R.M.S., D.T.B.); Duke University Medical Center, Durham, N.C. (S.L.G., R.K.D., J.O.M.); Mt. Sinai Medical Center, New York (P.A.P.); North Shore University Hospital, Manhasset, N.Y. (P.S.); the University of Maryland Cancer Center, Baltimore (E.J.L., C.A.S.); and Bowman Gray School of Medicine, Winston-Salem, N.C. (B.L.P.).

Address reprint requests to Dr. Stone at the Dana–Farber Cancer Institute, 44 Binney St., Boston, MA 02115.

Full Text of this Article

This article has been cited by other articles:

Attar, E. C., DeAngelo, D. J., Supko, J. G., D'Amato, F., Zahrieh, D., Sirulnik, A., Wadleigh, M., Ballen, K. K., McAfee, S., Miller, K. B., Levine, J., Galinsky, I., Trehu, E. G., Schenkein, D., Neuberg, D., Stone, R. M., Amrein, P. C. (2008). Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia. Clin. Cancer Res. 14: 1446-1454 [Abstract] [Full Text]
Sung, L., Nathan, P. C., Alibhai, S. M.H., Tomlinson, G. A., Beyene, J. (2007). Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection. ANN INTERN MED 147: 400-411 [Abstract] [Full Text]
Lancet, J. E., Gojo, I., Gotlib, J., Feldman, E. J., Greer, J., Liesveld, J. L., Bruzek, L. M., Morris, L., Park, Y., Adjei, A. A., Kaufmann, S. H., Garrett-Mayer, E., Greenberg, P. L., Wright, J. J., Karp, J. E. (2007). A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 109: 1387-1394 [Abstract] [Full Text]
Erba, H. P. (2007). Prognostic Factors in Elderly Patients with AML and the Implications for Treatment. ASH Education Book 2007: 420-428 [Abstract] [Full Text]
Farag, S. S., Archer, K. J., Mrozek, K., Ruppert, A. S., Carroll, A. J., Vardiman, J. W., Pettenati, M. J., Baer, M. R., Qumsiyeh, M. B., Koduru, P. R., Ning, Y., Mayer, R. J., Stone, R. M., Larson, R. A., Bloomfield, C. D. (2006). Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 108: 63-73 [Abstract] [Full Text]
Milligan, D. W., Wheatley, K., Littlewood, T., Craig, J. I. O., Burnett, A. K., for the NCRI Haematological Oncology Clinical Stud, (2006). Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood 107: 4614-4622 [Abstract] [Full Text]
Larson, R. A., Stone, R. M., Mayer, R. J., Schiffer, C. A. (2006). Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B.. Clin. Cancer Res. 12: 3556s-3563s [Abstract] [Full Text]
Krauth, M.-T., Florian, S., Bohm, A., Sonneck, K., Agis, H., Samorapoompichit, P., Hauswirth, A. W., Sperr, W. R., Valent, P. (2006). Immunological Characterization and Antibacterial Function of Persisting Granulocytes in Leukemic Patients Receiving Pulse Cytosine Arabinoside-Consolidation Chemotherapy on Days 1, 3, and 5. J. Immunol. 176: 1759-1768 [Abstract] [Full Text]
Stock, W. (2006). Controversies in Treatment of AML: Case-based Discussion. ASH Education Book 2006: 185-191 [Abstract] [Full Text]
Raez, L. E., Fein, S., Podack, E. R. (2005). Lung Cancer Immunotherapy. Clin Med Res 3: 221-228 [Abstract] [Full Text]
van der Holt, B., Lowenberg, B., Burnett, A. K., Knauf, W. U., Shepherd, J., Piccaluga, P. P., Ossenkoppele, G. J., Verhoef, G. E. G., Ferrant, A., Crump, M., Selleslag, D., Theobald, M., Fey, M. F., Vellenga, E., Dugan, M., Sonneveld, P., on behalf of the Dutch-Belgian Hemato-Oncology Coo, (2005). The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106: 2646-2654 [Abstract] [Full Text]
Marcucci, G., Mrozek, K., Ruppert, A. S., Maharry, K., Kolitz, J. E., Moore, J. O., Mayer, R. J., Pettenati, M. J., Powell, B. L., Edwards, C. G., Sterling, L. J., Vardiman, J. W., Schiffer, C. A., Carroll, A. J., Larson, R. A., Bloomfield, C. D. (2005). Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study. JCO 23: 5705-5717 [Abstract] [Full Text]
Amadori, S., Suciu, S., Jehn, U., Stasi, R., Thomas, X., Marie, J.-P., Muus, P., Lefrere, F., Berneman, Z., Fillet, G., Denzlinger, C., Willemze, R., Leoni, P., Leone, G., Casini, M., Ricciuti, F., Vignetti, M., Beeldens, F., Mandelli, F., De Witte, T., for the EORTC/GIMEMA Leukemia Groups, (2005). Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 106: 27-34 [Abstract] [Full Text]
Stull, D. M., Bilmes, R., Kim, H., Fichtl, R. (2005). Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia. Am J Health Syst Pharm 62: 83-87 [Full Text]
Marcucci, G., Mrozek, K., Ruppert, A. S., Archer, K. J., Pettenati, M. J., Heerema, N. A., Carroll, A. J., Koduru, P. R.K., Kolitz, J. E., Sterling, L. J., Edwards, C. G., Anastasi, J., Larson, R. A., Bloomfield, C. D. (2004). Abnormal Cytogenetics at Date of Morphologic Complete Remission Predicts Short Overall and Disease-Free Survival, and Higher Relapse Rate in Adult Acute Myeloid Leukemia: Results From Cancer and Leukemia Group B Study 8461. JCO 22: 2410-2418 [Abstract] [Full Text]
Sperr, W. R., Piribauer, M., Wimazal, F., Fonatsch, C., Thalhammer-Scherrer, R., Schwarzinger, I., Geissler, K., Knobl, P., Jager, U., Lechner, K., Valent, P. (2004). A Novel Effective and Safe Consolidation for Patients Over 60 Years with Acute Myeloid Leukemia: Intermediate Dose Cytarabine (2 x 1 g/m2 on Days 1, 3, and 5). Clin. Cancer Res. 10: 3965-3971 [Abstract] [Full Text]
Sekeres, M. A., Peterson, B., Dodge, R. K., Mayer, R. J., Moore, J. O., Lee, E. J., Kolitz, J., Baer, M. R., Schiffer, C. A., Carroll, A. J., Vardiman, J. W., Davey, F. R., Bloomfield, C. D., Larson, R. A., Stone, R. M. (2004). Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood 103: 4036-4042 [Abstract] [Full Text]
Stone, R. M., O'Donnell, M. R., Sekeres, M. A. (2004). Acute Myeloid Leukemia. ASH Education Book 2004: 98-117 [Abstract] [Full Text]
Lancet, J. E., Karp, J. E. (2003). Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 102: 3880-3889 [Abstract] [Full Text]
Byrd, J. C., Mrozek, K., Dodge, R. K., Carroll, A. J., Edwards, C. G., Arthur, D. C., Pettenati, M. J., Patil, S. R., Rao, K. W., Watson, M. S., Koduru, P. R. K., Moore, J. O., Stone, R. M., Mayer, R. J., Feldman, E. J., Davey, F. R., Schiffer, C. A., Larson, R. A., Bloomfield, C. D. (2002). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100: 4325-4336 [Abstract] [Full Text]
Stone, R. M. (2002). The Difficult Problem of Acute Myeloid Leukemia in the Older Adult. CA Cancer J Clin 52: 363-371 [Abstract] [Full Text]
Baer, M. R., George, S. L., Dodge, R. K., O'Loughlin, K. L., Minderman, H., Caligiuri, M. A., Anastasi, J., Powell, B. L., Kolitz, J. E., Schiffer, C. A., Bloomfield, C. D., Larson, R. A. (2002). Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100: 1224-1232 [Abstract] [Full Text]
Goldstone, A. H., Burnett, A. K., Wheatley, K., Smith, A. G., Hutchinson, R. M., Clark, R. E. (2001). Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 98: 1302-1311 [Abstract] [Full Text]
Stone, R. M., Berg, D. T., George, S. L., Dodge, R. K., Paciucci, P. A., Schulman, P. P., Lee, E. J., Moore, J. O., Powell, B. L., Baer, M. R., Bloomfield, C. D., Schiffer, C. A. (2001). Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98: 548-553 [Abstract] [Full Text]
Baer, M. R., Stewart, C. C., Dodge, R. K., Leget, G., Sule, N., Mrozek, K., Schiffer, C. A., Powell, B. L., Kolitz, J. E., Moore, J. O., Stone, R. M., Davey, F. R., Carroll, A. J., Larson, R. A., Bloomfield, C. D. (2001). High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 97: 3574-3580 [Abstract] [Full Text]
Appelbaum, F. R., Rowe, J. M., Radich, J., Dick, J. E. (2001). Acute Myeloid Leukemia. ASH Education Book 2001: 62-86 [Abstract] [Full Text]
Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., Wade, J. L. III, Winn, R. J., Wozniak, A. J., Somerfield, M. R., for the American Society of Clinical Oncology Gro, (2000). 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. JCO 18: 3558-3585 [Full Text]
Bruserud, O., Tjønnfjord, G., Gjertsen, B. T., Foss, B., Ernst, P. (2000). New Strategies in the Treatment of Acute Myelogenous Leukemia: Mobilization and Transplantation of Autologous Peripheral Blood Stem Cells in Adult Patients. Stem Cells 18: 343-351 [Abstract] [Full Text]
Estey, E. H. (2000). How I treat older patients with AML. Blood 96: 1670-1673 [Full Text]
Harousseau, J. L., Witz, B., Lioure, B., Hunault-Berger, M., Desablens, B., Delain, M., Guilhot, F., Le Prise, P. Y., Abgrall, J. F., Deconinck, E., Guyotat, D., Vilque, J. P., Casassus, P., Tournilhac, O., Audhuy, B., Solary, E. (2000). Granulocyte Colony-Stimulating Factor After Intensive Consolidation Chemotherapy in Acute Myeloid Leukemia: Results of a Randomized Trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. JCO 18: 780-780 [Abstract] [Full Text]
Archimbaud, E., Ottmann, O. G., Yin, J. A. L., Lechner, K., Dombret, H., Sanz, M. A., Heil, G., Fenaux, P., Brugger, W., Barge, A., O'Brien-Ewen, C., Matcham, J., Hoelzer, D. (1999). A Randomized, Double-Blind, Placebo-Controlled Study With Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF) as an Adjunct to Chemotherapy for Adults With De Novo Acute Myeloid Leukemia. Blood 94: 3694-3701 [Abstract] [Full Text]
Lowenberg, B., Downing, J. R., Burnett, A. (1999). Acute Myeloid Leukemia. NEJM 341: 1051-1062 [Full Text]
Lee, E. J., George, S. L., Caligiuri, M., Szatrowski, T. P., Powell, B. L., Lemke, S., Dodge, R. K., Smith, R., Baer, M., Schiffer, C. A. (1999). Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With Acute Myeloid Leukemia: Results of Cancer and Leukemia Group B Study 9420. JCO 17: 2831-2831 [Abstract] [Full Text]
Witz, F., Sadoun, A., Perrin, M.-C., Berthou, C., Briere, J., Cahn, J.-Y., Lioure, B., Witz, B., Francois, S., Desablens, B., Pignon, B., Le Prise, P.-Y., Audhuy, B., Caillot, D., Casassus, P., Delain, M., Christian, B., Tellier, Z., Polin, V., Hurteloup, P., Harousseau, J.-L. (1998). A Placebo-Controlled Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Administered During and After Induction Treatment for De Novo Acute Myelogenous Leukemia in Elderly Patients. Blood 91: 2722-2730 [Abstract] [Full Text]
Heil, G., Hoelzer, D., Sanz, M. A., Lechner, K., Liu Yin, J. A., Papa, G., Noens, L., Szer, J., Ganser, A., O'Brien, C., Matcham, J., Barge, A. (1997). A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia. Blood 90: 4710-4718 [Abstract] [Full Text]
Talcott, J. A. (1997). Outpatient Management of Febrile Neutropenia: Should We Change the Standard of Care?. The Oncologist 2: 365-373 [Abstract] [Full Text]
Mrozek, K., Heinonen, K., Lawrence, D., Carroll, A. J., Koduru, P. R.K., Rao, K. W., Strout, M. P., Hutchison, R. E., Moore, J. O., Mayer, R. J., Schiffer, C. A., Bloomfield, C. D. (1997). Adult Patients With De Novo Acute Myeloid Leukemia and t(9; 11)(p22; q23) Have a Superior Outcome to Patients With Other Translocations Involving Band 11q23: A Cancer and Leukemia Group B Study. Blood 90: 4532-4538 [Abstract] [Full Text]
Ketley, N. J., Allen, P. D., Kelsey, S. M., Newland, A. C. (1997). Modulation of Idarubicin-Induced Apoptosis in Human Acute Myeloid Leukemia Blasts by All-Trans Retinoic Acid, 1,25(OH)2 Vitamin D3, and Granulocyte-Macrophage Colony-Stimulating Factor. Blood 90: 4578-4587 [Abstract] [Full Text]
Lowenberg, B., Suciu, S., Archimbaud, E., Ossenkoppele, G., Verhoef, G.E.G., Vellenga, E., Wijermans, P., Berneman, Z., Dekker, A.W., Stryckmans, P., Schouten, H., Jehn, U., Muus, P., Sonneveld, P., Dardenne, M., Zittoun, R. (1997). Use of Recombinant Granulocyte-Macrophage Colony-Stimulating Factor During and After Remission Induction Chemotherapy in Patients Aged 61�Years and Older With Acute Myeloid Leukemia (AML): Final Report of AML-11, a Phase III Randomized Study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 90: 2952-2961 [Abstract] [Full Text]
Leith, C. P., Kopecky, K. J., Godwin, J., McConnell, T., Slovak, M. L., Chen, I-M., Head, D. R., Appelbaum, F. R., Willman, C. L. (1997). Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study. Blood 89: 3323-3329 [Abstract] [Full Text]
Moore, J. O., Dodge, R. K., Amrein, P. C., Kolitz, J., Lee, E. J., Powell, B., Godfrey, S., Robert, F., Schiffer, C. A. (1997). Granulocyte Colony-Stimulating Factor (Filgrastim) Accelerates Granulocyte Recovery After Intensive Postremission Chemotherapy for Acute Myeloid Leukemia With Aziridinyl Benzoquinone and Mitoxantrone: Cancer and Leukemia Group B Study 9022�. Blood 89: 780-788 [Abstract] [Full Text]
Hamblin, T. J. (1995). Disappointments in Treating Acute Leukemia in the Elderly. NEJM 332: 1712-1714 [Full Text]

Comments and questions? Please contact us.